Abstract. Fibroblast growth factor receptor 3 (FGFR3) is a high frequency mutant gene in bladder cancer (BCa) and has become a promising therapeutic target due to its involvement in cell proliferation and migration. However, whether and how FGFR3 mutations affects BCa cell chemosensitivity is unknown. The current study aimed to elucidate the role of the FGFR3 S249C mutation in the development of chemoresistance in BCa cells. The results revealed that 97-7 (FGFR3 S249C ) cells had decreased sensitivity to cisplatin compared with 5637 (FGFR3 WT ) and T24 (FGFR3 WT ) cells. The ratio of phosphorylated-Akt/total-Akt was higher in 97-7 (FGFR3 S249C ) cells, which was reversed by knockdown of FGFR3. Furthermore, inhibition of Akt signaling by GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 (FGFR3 S249C ) cells. GDC0068 or LY294002 was also revealed to augment the effects of cisplatin on 97-7 (FGFR3 S249C ) cell proliferation and apoptosis. The results of the present study demonstrated that the FGFR3 S249C mutation promotes chemoresistance in BCa cells by activating the Akt signaling pathway. The FGFR3 S249C mutation may therefore be used as a predictor of chemosensitivity in patients with BCa.
Introduction
Bladder cancer (BCa) is the second most common malignancy of the genitourinary tract (1), with ~76,960 new diagnoses and 16,390 BCa associated deaths reported in the USA in 2016 (2) . Since 1984, the number of BCa diagnoses has increased by~36% per year (2) . Urothelial carcinoma (transitional cell carcinoma) is the most common BCa (>90%) and is generally classified as non-muscle invasive BCa (NMIBC) or muscle invasive BCa (MIBC), according to the nature of the tumor (3). Among NMIBC cases, 50-70% recur after treatment and an estimated 10-15% develop into MIBC, which possesses the characteristics of metastatic malignant tumors, exhibiting a 5-year survival rate of 50-60% (4, 5) . When MIBC progresses to metastatic BCa, the 5-year survival rate decreases to 5% (4) . Cisplatin-based combination chemotherapy is widely used in MIBC treatment and increases survival (6) . However, the response rate to chemotherapy is only ~50% and resistance to cisplatin is considered to be the principal cause of this poor response (7) . An in-depth study of possible factors affecting cisplatin sensitivity is therefore required to identify potential novel therapeutic targets for BCa and subsequently improve clinical treatment outcomes.
Fibroblast growth factor receptor 3 (FGFR3), one of the four highly conserved FGFRs, is a receptor tyrosine kinase involved in cancer cell proliferation and migration (8) . A total of 11 different FGFR3-activating missense mutations have been reported in ~70% of NMIBC and 15% of MIBC cases (8, 9 ). An analysis of the latest mutation data of BCa tissue from The Cancer Genome Atlas database (http://www. cbioportal. org/index.do) revealed that 14% of patients with BCa exhibited FGFR3-activating point mutations (10, 11) . Among the FGFR3 mutations, S249C accounted for 53.4% and was the most frequent mutation in BCa (10, 11) . S249C, located on exon 7, induces a substitution of serine with cysteine at codon 249. This substitution leads to a ligand-independent dimerization and the auto-phosphorylation of FGFR3, which results in the continued activation of downstream proliferative pathways (12) . A study has demonstrated that FGFR3 may be an oncogenic driver of BCa and hence targeting FGFR3 may be a beneficial therapeutic approach (13 no. SA00001-2; Proteintech Group, Inc.) antibodies were incubated at room temperature for 2 h and blots were developed using the SuperSignal TM West Dura Extended Duration Substrate reagent (Thermo Fisher Scientific, Inc.) with an Amersham Imager 600 (GE Healthcare). Band intensity was determined by ImageJ 2X software (National Institutes of Health) and normalized to β-actin. The activation of the Akt signaling pathway was determined using the ratio of P-Akt/T-Akt.
Reverse transcription-quantitative (RT-q) PCR.
Total RNA was extracted from 97-7 cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) and was reverse-transcribed using a PrimeScript RT reagent kit with a gDNA Eraser (Takara Bio, Inc.) for cDNA synthesis and genomic DNA removal. RT-qPCR was performed using a QuantiNova TM SYBR Green PCR mix kit (Qiagen GmbH) and performed using Applied Biosystems Prism 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). Amplification was performed according to the reaction conditions of 95˚C for 10 min; 95˚C for 10 sec, 60˚C for 30 sec, for 40 cycles. The relative expression of FGFR3 was compared with that of β-actin and fold changes were calculated using the 2 -∆∆Ct method (15) . The primers used were as follows: FGFR3 forward, 5'-TGC GTC GTG GAG AAC AAG TTT-3' and reverse, 5'-GCA CGG TAA CGT AGG GTG TG-3'; β-actin forward, 5'-CTG GAA CGG TGA AGG TGA CA-3' and reverse, 5'-AAG GGA CTT CCT GTA ACA ATG CA-3'.
RNA interference assay. RNA interference was used to knockdown the expression of FGFR3 in 97-7 (FGFR3 S249C ) cells. Small interfering RNA (siRNA) for FGFR3 (siRNA-FGFR3) and scrambled negative control (NC) siRNA (siRNA-NC) were obtained from Shanghai GenePharma Co., Ltd. 97-7 (FGFR3 S249C ) cells were transfected with 30 nM siRNA using lipofectamine RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C in six-well plates. After 48 h, cells were collected and used for RNA and protein extraction. The siRNA sequences were as follows: siRNA-NC forward, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and reverse, ACG UGA CAC GUU CGG AGA ATT; siRNA-FGFR3 forward, 5'-GCU GAA AGA CGA UGC CAC UTT-3' and reverse, 5'-AGU GGC AUC GUC UUU CAG CTT-3'.
Cell proliferation assay. A CCK-8 assay was performed to determine cell proliferation as described in a previous study (16) . 97-7 (FGFR3 S249C ) cells were seeded into 96-well plates at a density of 5,000 cells per well and incubated at 37˚C with 5 µg/ml cisplatin with or without 10 µM GDC0068 and 10 µg/ml cisplatin with or without 20 µM LY294002. These concentrations were selected based on the IC 50 values of treatments. Following incubation for 1, 2, 3, and 4 days, the cell morphology was assessed using a light microscope (Nikon Corporation), and cell proliferation was detected using a CCK-8 assay kit (Dojindo Molecular Technologies, Inc.) in accordance with the manufacturer's protocol. OD values at 450 nm were measured using a microplate reader.
Cell apoptosis analysis. Cell apoptosis analysis was performed using an Annexin V-FITC/propidium Iodide (PI) Cell Apoptosis Analysis kit according to manufacturer's protocol (Absin Bioscience, Inc.). Cells were treated with 5 µg/ml cisplatin with or without 10 µM GDC0068 and 10 µg/ml cisplatin with or without 20 µM LY294002 at 37˚C for 72 h. 97-7 (FGFR3 S249C ) cells were harvested and washed twice in ice-cold PBS, resuspended in 300 µl binding buffer (Absin Bioscience, Inc.) and incubated with 5 µl Annexin V-FITC and 10 µl PI in the dark for 15 min at room temperature. After adding 200 µl PBS to each sample, cell apoptosis was detected within 1 h using a flow cytometer (Beckman Coulter, Inc.). The results were analysed using FlowJo v10 software (FlowJo LLC).
Statistical analysis. Analyses were performed using SPSS 23.0 software (IBM Corp.). Statistical analysis was performed using a two-tailed Student's t-test or one-way ANOVA, followed by a Newman-Keuls or a Dunnett's multiple comparison test. All data were presented as the mean ± SEM. P<0.05 was considered to indicate a statistically significant difference.
Results

97-7 (FGFR3
S249C
) cells are more resistant to cisplatin treatment compared with 5637 (FGFR3 WT ) and T24 (FGFR3 WT ) cells. Cell viability was assessed using a CCK-8 assay after treatment with different concentrations of cisplatin for 48 h, to determine whether cisplatin sensitivity was significantly different between the BCa cells carrying the S249C mutant FGFR3 (97-7) and wild type FGFR3 (5637 and T24). The results revealed that cell viability was reduced following cisplatin treatment in all three cell lines (Fig. 1A, C and E (17, 18) . It has also been revealed that the phosphorylation of FGFR3 leads to the activation of several downstream signaling cascades, including PI3K-Akt-mTOR and Ras-Raf-mitogen activated protein kinase (MAPK) (13, 19) .
These data revealed that FGFR3 S249C mutations in BCa cells may induce chemoresistance by activating Akt signaling. Therefore, levels of T-Akt and P-Akt were detected in the present study using western blot analysis in 97-7 (FGFR3 S249C ), 5637 (FGFR3 WT ) and T24 (FGFR3 WT ) cells. The activation of the Akt signaling pathway was determined using the ratio of P-Akt/T-Akt. As presented in Fig. 2A -C, 97-7 (FGFR3 S249C ) cells exhibited increased P-Akt levels compared with 5637 (FGFR3 WT ) and T24 (FGFR3 WT ) cells, although no marked change in T-Akt levels were observed (Fig. 2A) . The elevated P-Akt/T-Akt ratio in 97-7(FGFR3 S249C ) cells indicated the activation of Akt signaling (Fig. 2B) .
To further verify the regulatory effect of FGFR3 on Akt signaling, the P-Akt/T-Akt ratio was assessed in 97-7 (FGFR3 S249C ) cells after FGFR3 knockdown using siRNA for 48 h. Consistent with a previous study (19) , the knockdown of FGFR3, which decreased FGFR3 mRNA and protein expression levels ( Fig. 2C and D) , resulted in a ~30% decrease in the ratio of P-Akt/T-Akt ( Fig. 2E and F) . The results indicated that the FGFR3 S249C mutation, which leads to the auto-phosphorylation of FGFR3 in 97-7 (FGFR3 S249C ) cells, augments Akt signaling.
Inhibition of the Akt signaling pathway sensitizes 97-7 (FGFR3
S249C
) cells to cisplatin. To determine the role of Akt signaling in cisplatin resistance, 97-7 (FGFR3 S249C ) cells treated with cisplatin were subsequently treated with or without the Akt inhibitor (GDC0068) or the PI3K inhibitor (LY294002) for 48 h, following which cell viability was assessed. GDC0068 <16 µM and LY294002 <80 µM did not affect cell viability in 97-7 (FGFR3 S249C ) cells (Fig. 3A and B) . Western blot analysis revealed that 20 µM LY294002 decreased the level of P-Akt and inhibited the activation of Akt signaling (Fig. 3C) . GDC0068, is an ATP-competitive Akt inhibitor (20) , which occupies the ATP binding pocket of Akt kinases and facilitates intramolecular interactions of phosphorylated T308/S473 with two residues in the catalytic cleft (R273, H194), results in restricting phosphatase access and sustaining Akt phosphorylation (21) . Therefore, as other previous studies (20, 22, 23) , although GDC0068 inhibits the activity of Akt signaling, a high level of P-Akt can be detected after GDC0068 treatment (Fig. 3C) . Based on these data, 10 µM GDC0068 and 20 µM LY294002 were utilized in subsequent combined treatment studies. GDC0068 and LY294002 increased the sensitivity of 97-7 (FGFR3 S249C ) cells to cisplatin (Fig. D and F) . The IC 50 value was reduced from 44.11 µg/ml for treatment with cisplatin alone to 4.17 and 8.91 µg/ml when administered in combination with GDC0068 and LY294002, respectively ( Fig. 3E and G) . The results revealed that the Akt signaling pathway may be involved in the chemoresistance of 97-7 (FGFR3 S249C ) cells.
Inhibition of the Akt signaling pathway augments the effects of cisplatin on 97-7 (FGFR3 S249C ) cell proliferation and apoptosis.
To assess the potential role of the Akt signaling pathway in cisplatin-induced apoptosis, the effect of Akt inhibitors on the proliferation and apoptosis of 97-7 (FGFR3 S249C ) cells was determined following treatment with cisplatin. The results revealed that cisplatin treatment altered the cell from fusiform to round, and reduced cell numbers, which were more pronounced after combinational treatment with GDC0068 or LY294002 (Fig. 4A and B) . The suppression of cell proliferation by cisplatin was more apparent with prolonged treatments and the combined treatment of cisplatin with GDC0068 or LY294002 significantly increased the effect of cisplatin on the proliferation of 97-7 cells (FGFR3 S249C ; Fig. 4C and D) . After 72 h of treatment, 5 and 10 µg/ml cisplatin significantly increased apoptosis compared with untreated cells (Fig. 4E and F) . Furthermore, GDC0068 and LY294002 in combination with cisplatin significantly increased apoptosis by 53.3% and 25%, respectively, compared with cisplatin treatment alone (the numbers of apoptotic cells were 23% vs. 15% and 25% vs. 20%, respectively; Fig. 4E and F) . The results of the current study indicate that the Akt signaling pathway is activated in FGFR3 S249C mutant BCa cells, resulting in the promotion of cisplatin resistance, and the chemical inhibition of the Akt signaling pathway in 97-7 (FGFR3 S249C ) cells indicated improved chemosensitivity (Fig. 5) .
Discussion
BCa is the most common malignant carcinoma of the urinary system (1). Despite initial sensitivity to standard first-line combination cisplatin-based chemotherapy, the overall prognosis of MIBC is poor (8, 24) . Since chemoresistance is a critical factor that effects clinical treatment outcomes (7) , studies that assess and develop efficient chemosensitizers have become an urgent requirement. FGFR3, a high-frequency mutant gene in BCa with known regulatory roles in tumor progression, has become a promising therapeutic target (8, 25, 26) . In the present study, the role of S249C mutant FGFR3 was elucidated in the development of BCa cell chemoresistance. The results revealed that BCa cells carrying FGFR3 S249C exhibited a lower sensitivity to cisplatin. The FGFR3 S249C mutation in BCa cells also activated Akt signaling and the chemical inhibition of the Akt signaling pathway in 97-7 (FGFR3 S249C ) cells improved chemosensitivity and enhanced the cisplatin-induced suppression of cell proliferation and apoptosis induction.
Conventional chemotherapeutic drugs, including platinum and fluorouracil induce an anti-tumor effect by damaging DNA and promoting tumor cell apoptosis (27) . As cisplatin-based combination chemotherapy is the most important therapeutic strategy for MIBC (6) , cisplatin resistance in BCa cells was assessed in the current study. S249C accounts for >50% of all FGFR3 point mutations in BCa (10, 11) and therefore the effect of FGFR3 S249C on BCa cell chemosensitivity was also assessed in the present study. The cell line 97-7 was utilized as it carried the FGFR3 S249C mutation without additional mutations in Ras, Akt or PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (12, 14) . The 97-7 cell line was established from a primary tumor with invasive transitional cell carcinoma (Grade II/III Stage I) and was demonstrated to express similar FGFR3 levels as low-stage and low-grade tumors (28) . In the present study, it was demonstrated that 97-7 cells carrying S249C mutant FGFR3 exhibited a higher IC 50 value for cisplatin, indicating that the FGFR3 S249C mutation reduced BCa cell sensitivity to cisplatin. This result indicated that the FGFR3 S249C mutation may be developed as a predictor of chemosensitivity in patients with BCa.
The mechanisms underlying the development of chemoresistance are complex and include increased drug efflux, alterations in chemotherapy drug targets and the abnormal activation of key signaling pathways such as PI3K/Akt and signal transducer and activator of transcription 3 (17, 18) .
Evidence from previous studies has demonstrated that FGFR3 phosphorylation activates several signaling pathways, including the PI3K-Akt-mTOR and Ras-Raf-MAPK pathway (13, 19) . The Akt signaling pathway may therefore be involved in the FGFR3 S249C mutation-induced chemoresistance of BCa cells. In the current study, the ratio of P-Akt/T-Akt increased in 97-7 (FGFR3 S249C ) cells compared with 5637 (FGFR3 WT ) and T24 (FGFR3 WT ; Fig. 2A and B) . Furthermore, as reported previously (19) , the P-Akt/T-Akt ratio in 97-7 ( Previous studies have reported that high concentrations of Akt inhibitor (GDC0068) and PI3K inhibitor (LY294002) promotes tumor cell apoptosis and inhibits proliferation (29) (30, 31) . To avoid these effects, the current study utilized low concentrations of GDC0068 (10 µM) and LY294002 (20 µM). Consistent with previous studies (30, 32) , 20 µM LY294002 inhibited the Akt signaling pathway and reduced P-Akt levels. GDC0068, is an ATP-competitive Akt inhibitor that occupies the ATP binding pocket of Akt kinases and facilitates intramolecular interactions, resulting restricts phosphatase access and sustains Akt phosphorylation (15, 21) . This may explain the high P-Akt level detected after treatment with 10 µM GDC0068 in the current study and other previous studies (20, 22, 23) . The inhibition of Akt signaling with GDC0068 or LY294002 sharply decreased the IC 50 of cisplatin and improved the chemosensitivity of BCa cells carrying S249C mutant FGFR3, enhancing the cisplatin-mediated reduction of proliferation and the induction of apoptosis. The results verified the hypothesis that the Akt signaling pathway may be involved in the FGFR3 S249C mutation-induced chemoresistance of BCa cells.
Currently, several Akt inhibitors including GDC0068, MK2206, GSK2110183 and AZD5363 have entered phase II of clinical trials, but the efficacy of therapies with Akt inhibitors as single agents is limited (33) . A previous study therefore combine Akt inhibitors with other compounds to increase efficacy (30) . For example, a recent study combining cisplatin with MK2206 showed synergistic activity in vivo and in vitro in lung cancer (34) . Furthermore, MK2206 also increased the sensitivity to paclitaxel and carboplatin in melanoma cell lines (35) . The results of the current study demonstrated that the use of Akt inhibitors combined with cisplatin-based chemotherapy may be used as a potential treatment strategy for patients with BCa carrying the FGFR3 S249C mutation. 97-7 (FGFR3 S249C ) cells have not been demonstrated to produce tumors in subcutaneous xenografts in nude mice, which may be due to the dependence of tumor cells on tissue-specific microenvironmental factors (12) . However, the current study was not able to verify the effects of the FGFR3 S249C mutation on BCa chemosensitivity in vivo. It is therefore important to develop a FGFR3 mutant BCa in vivo model and in particular, an in-situ model, for studying the effects of the FGFR3 mutation on chemoresistance and determining associated underlying mechanisms.
In summary, the in vitro analysis used in the current study demonstrated that the FGFR3 S249C mutation in BCa cells promoted chemoresistance, at least in part, via the activation of the Akt signaling pathway. The results also indicated that the FGFR3 S249C mutation may be developed as a biomarker for the detection of chemosensitivity and that targeting Akt signaling may be a promising treatment strategy for improving chemosensitivity in patients with BCa carrying the FGFR3 S249C mutation.
